Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Assertio Holdings, Inc. stock logo
ASRT
Assertio
$0.66
-3.7%
$0.66
$0.51
$1.80
$63.24M0.29534,143 shs151,355 shs
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
$0.01
$0.02
$0.01
$0.02
$147K0.7418,907 shs7,027 shs
Diffusion Pharmaceuticals Inc. stock logo
DFFN
Diffusion Pharmaceuticals
$4.64
$2.76
$7.40
$8.98M1.7810,937 shs351,000 shs
Heatwurx Inc. stock logo
PCSA
Heatwurx
$0.21
-4.2%
$0.26
$0.15
$3.10
$2.44M1.35.31 million shs4.55 million shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Assertio Holdings, Inc. stock logo
ASRT
Assertio
-0.77%+4.48%+8.51%+8.95%-58.69%
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
0.00%0.00%0.00%0.00%-76.47%
Diffusion Pharmaceuticals Inc. stock logo
DFFN
Diffusion Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Heatwurx Inc. stock logo
PCSA
Heatwurx
-5.26%+10.58%-17.10%-20.66%-88.09%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Assertio Holdings, Inc. stock logo
ASRT
Assertio
1.8537 of 5 stars
3.50.00.00.02.20.81.3
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Diffusion Pharmaceuticals Inc. stock logo
DFFN
Diffusion Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Heatwurx Inc. stock logo
PCSA
Heatwurx
3.1608 of 5 stars
3.52.00.00.03.81.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Assertio Holdings, Inc. stock logo
ASRT
Assertio
3.00
Buy$2.75316.48% Upside
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
0.00
N/AN/AN/A
Diffusion Pharmaceuticals Inc. stock logo
DFFN
Diffusion Pharmaceuticals
0.00
N/AN/AN/A
Heatwurx Inc. stock logo
PCSA
Heatwurx
3.00
Buy$2.00873.71% Upside

Current Analyst Ratings Breakdown

Latest BLPH, PCSA, ASRT, and DFFN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/30/2025
Heatwurx Inc. stock logo
PCSA
Heatwurx
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$6.00 ➝ $2.00
5/19/2025
Assertio Holdings, Inc. stock logo
ASRT
Assertio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.50 ➝ $3.50
5/13/2025
Assertio Holdings, Inc. stock logo
ASRT
Assertio
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Assertio Holdings, Inc. stock logo
ASRT
Assertio
$124.96M0.51$0.05 per share14.08$1.27 per share0.52
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
$5.64M0.03N/AN/A$0.27 per share0.04
Diffusion Pharmaceuticals Inc. stock logo
DFFN
Diffusion Pharmaceuticals
N/AN/AN/AN/A$6.97 per shareN/A
Heatwurx Inc. stock logo
PCSA
Heatwurx
N/AN/AN/AN/A$0.46 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Assertio Holdings, Inc. stock logo
ASRT
Assertio
-$21.58M-$0.32N/A22.01N/A-25.72%-24.87%-10.87%8/6/2025 (Estimated)
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
-$19.83M-$0.84N/AN/AN/AN/AN/AN/A
Diffusion Pharmaceuticals Inc. stock logo
DFFN
Diffusion Pharmaceuticals
-$15.59MN/A0.00N/AN/AN/A-69.96%-62.98%N/A
Heatwurx Inc. stock logo
PCSA
Heatwurx
-$11.85M-$3.08N/AN/AN/AN/A-319.56%-232.40%8/12/2025 (Estimated)

Latest BLPH, PCSA, ASRT, and DFFN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Heatwurx Inc. stock logo
PCSA
Heatwurx
-$0.23N/AN/AN/AN/AN/A
8/6/2025Q2 2025
Assertio Holdings, Inc. stock logo
ASRT
Assertio
-$0.06N/AN/AN/A$27.86 millionN/A
5/12/2025Q1 2025
Assertio Holdings, Inc. stock logo
ASRT
Assertio
-$0.06-$0.14-$0.08-$0.14$27.52 million$26.49 million
5/8/2025Q1 2025
Heatwurx Inc. stock logo
PCSA
Heatwurx
-$0.77-$0.30+$0.47-$0.30N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Assertio Holdings, Inc. stock logo
ASRT
Assertio
N/AN/AN/AN/AN/A
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
N/AN/AN/AN/AN/A
Diffusion Pharmaceuticals Inc. stock logo
DFFN
Diffusion Pharmaceuticals
N/AN/AN/AN/AN/A
Heatwurx Inc. stock logo
PCSA
Heatwurx
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Assertio Holdings, Inc. stock logo
ASRT
Assertio
0.36
1.66
1.35
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
N/AN/AN/A
Diffusion Pharmaceuticals Inc. stock logo
DFFN
Diffusion Pharmaceuticals
N/A
10.71
10.71
Heatwurx Inc. stock logo
PCSA
Heatwurx
N/A
2.93
2.93

Institutional Ownership

CompanyInstitutional Ownership
Assertio Holdings, Inc. stock logo
ASRT
Assertio
48.96%
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
10.61%
Diffusion Pharmaceuticals Inc. stock logo
DFFN
Diffusion Pharmaceuticals
9.95%
Heatwurx Inc. stock logo
PCSA
Heatwurx
91.93%

Insider Ownership

CompanyInsider Ownership
Assertio Holdings, Inc. stock logo
ASRT
Assertio
4.00%
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
5.20%
Diffusion Pharmaceuticals Inc. stock logo
DFFN
Diffusion Pharmaceuticals
1.80%
Heatwurx Inc. stock logo
PCSA
Heatwurx
9.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Assertio Holdings, Inc. stock logo
ASRT
Assertio
2095.78 million91.95 millionOptionable
Bellerophon Therapeutics, Inc. stock logo
BLPH
Bellerophon Therapeutics
2012.23 million11.60 millionNo Data
Diffusion Pharmaceuticals Inc. stock logo
DFFN
Diffusion Pharmaceuticals
132.04 million2.00 millionNot Optionable
Heatwurx Inc. stock logo
PCSA
Heatwurx
2011.88 million10.74 millionNot Optionable

Recent News About These Companies

Processa Pares Gains on Equity Offer News

New MarketBeat Followers Over Time

Media Sentiment Over Time

Assertio stock logo

Assertio NASDAQ:ASRT

$0.66 -0.03 (-3.70%)
Closing price 04:00 PM Eastern
Extended Trading
$0.67 +0.01 (+1.47%)
As of 06:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Bellerophon Therapeutics stock logo

Bellerophon Therapeutics NASDAQ:BLPH

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Diffusion Pharmaceuticals stock logo

Diffusion Pharmaceuticals NASDAQ:DFFN

Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company was founded in 2001 and is based in Charlottesville, Virginia.

Heatwurx stock logo

Heatwurx NASDAQ:PCSA

$0.21 -0.01 (-4.15%)
Closing price 04:00 PM Eastern
Extended Trading
$0.21 +0.00 (+0.29%)
As of 06:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.